Cytoplasmic Cyclin E Mediates Resistance to Aromatase Inhibitors in Breast Cancer.

ABSTRACT: Purpose: Preoperative aromatase inhibitor (AI) therapy has demonstrated efficacy in hormone receptor (HR)-positive postmenopausal breast cancer. However, many patients have disease that is either intrinsically resistant to AIs or that responds initially but develops resistance after prolonged exposure. We have shown that patients with breast tumors expressing the deregulated forms of cyclin E [low molecular weight forms (LMW-E)] have poor overall survival. Herein, we hypothesize that LMW-E expression can identify HR-positive tumors that are unresponsive to neoadjuvant AI therapy due to the inability of AIs to induce a cytostatic effect.Experimental Design: LMW-E was examined in breast cancer specimens from 58 patients enrolled in the American College of Surgeons Oncology Grou

SUBMITTER: Doostan I 

PROVIDER: S-EPMC5768442 | biostudies-literature | 2017 Dec

REPOSITORIES: biostudies-literature